Biotechnology Europe's largest biotech firm Actelion (SIX: ATLN) revealed yesterday that it may report an operating loss, because, in the absence of a judgment in regard to the law suit with Japanese drugmaker Asahi Kasei Pharma (case number CIV 478533, Superior Court of the State of California, County of San Mateo, USA), the company will make a provision for the full award of damages announced last month. 30 June 2011